PMID- 19006541
OWN - NLM
STAT- MEDLINE
DCOM- 20110506
LR  - 20100826
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 29
IP  - 2
DP  - 2009 Jan
TI  - On-demand requirements of patients with endoscopy-negative gastro-oesophageal 
      reflux disease: H2-blocker vs. proton pump inhibitor.
PG  - 207-12
LID - 10.1111/j.1365-2036.2008.03877.x [doi]
AB  - BACKGROUND: It is questionable whether a symptomatic condition with few serious 
      medical consequences requires proton pump inhibitor (PPI) treatment. If 
      effective, a less-potent treatment may be preferable. AIM: To compare an 
      H2-blocker in an effervescent formulation with a PPI in on-demand treatment of 
      endoscopy-negative gastro-oesophageal reflux disease (GERD). METHODS: Included 
      were patients with heartburn and/or acid regurgitation for at least 3 months 
      duration, a negative endoscopy and a positive response to 7 days of lansoprazole 
      60 mg daily. Following pH-metry, the patients were randomized to receive either 
      ranitidine effervescent tablets 75 mg or lansoprazole capsules 15 mg to a maximum 
      of four per day on-demand. The numbers taken were registered monthly for 6 
      months. If treatment was unsuccessful (lack of efficacy or side effects), 
      patients were registered as failures. RESULTS: One hundred and three patients 
      were included and 63 were considered for statistical analysis; 32 on lansoprazole 
      and 31 on ranitidine. Seventeen (55%) on ranitidine and four (13%) on 
      lansoprazole failed. The average number of tablets per day was 1.2 in the 
      lansoprazole group and 3.1 in the ranitidine group. CONCLUSIONS: On-demand 
      treatment in patients with endoscopy-negative GERD gives a high success rate with 
      a fairly low dose of PPI. The H2-blocker had significantly less success; 
      nevertheless, almost half were satisfied with the treatment.
FAU - Juul-Hansen, P
AU  - Juul-Hansen P
AD  - Rasta Medical Centre, Lorenskog, Norway. paul.juul-hansen@broadpark.no
FAU - Rydning, A
AU  - Rydning A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081022
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Statistics as Topic
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/11/14 09:00
MHDA- 2011/05/07 06:00
CRDT- 2008/11/14 09:00
PHST- 2008/11/14 09:00 [pubmed]
PHST- 2011/05/07 06:00 [medline]
PHST- 2008/11/14 09:00 [entrez]
AID - APT3877 [pii]
AID - 10.1111/j.1365-2036.2008.03877.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2009 Jan;29(2):207-12. doi: 
      10.1111/j.1365-2036.2008.03877.x. Epub 2008 Oct 22.